{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:34:24Z","timestamp":1791646464224,"version":"4.3.4"},"reference-count":130,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Pulmonary hypertension (PH) is a progressive disorder characterized by obstructive changes in the pulmonary vasculature, leading to increased pulmonary vascular resistance (PVR), right ventricular (RV) strain, and eventual RV failure (RVF). Despite advancements in medical therapy, PH remains associated with significant morbidity and mortality, particularly in children. RVF is a clinical syndrome resulting from complex structural and functional remodeling of the right heart, leading to inadequate pulmonary circulation, reduced cardiac output, and elevated venous pressure. Management paradigms for pediatric PH diverge significantly from those in adults, particularly due to the predominance of congenital heart disease (CHD) and the dynamic nature of pediatric cardiovascular and pulmonary development. CHD remains a principal driver of PH in children, and its associated pathophysiology demands a nuanced approach. In patients with unrepaired left-to-right shunts, elevated pulmonary blood flow can lead to progressive pulmonary vascular remodeling and increased PVR. The postoperative persistence or progression of PH may occur if irreversible vascular changes have already developed. Current PH treatments primarily focus on reducing PVR, yet distinguishing between therapeutic approaches that target the pulmonary vasculature and those aimed at improving RV function remain challenging. In pediatric patients with progressive PH despite optimal therapy, additional targeted interventions may be necessary to mitigate RV dysfunction and disease progression. This review provides a comprehensive analysis of the mechanisms underlying RVF in PH, incorporating insights from clinical studies in adults and experimental models, while highlighting the unique considerations in children. Furthermore, it explores current pharmacological and interventional treatment strategies, emphasizing the need for novel therapeutic approaches aimed at directly reversing RV remodeling. Given the complexities of RV adaptation in pediatric PH, further research into disease-modifying treatments and innovative interventions is crucial to improving long-term outcomes in affected children.<\/jats:p>","DOI":"10.3390\/children12040476","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T05:59:00Z","timestamp":1744091940000},"page":"476","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Mechanism and Treatment of Right Ventricular Failure Due to Pulmonary Hypertension in Children"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9530-8785","authenticated-orcid":false,"given":"Bibhuti B.","family":"Das","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Cardiology, University of Mississippi Medical Center, Jackson, MS 39216, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.healun.2013.10.015","article-title":"Right heart failure: Toward a common language","volume":"33","author":"Mehra","year":"2014","journal-title":"J. Heart Lung Transplant."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ejhf.3024","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"26","author":"Mcdonagh","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_3","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e578","DOI":"10.1161\/CIR.0000000000000560","article-title":"Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association","volume":"137","author":"Konstam","year":"2018","journal-title":"Circulation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100203","DOI":"10.1016\/j.jhlto.2024.100203","article-title":"Contemporary Treatment of Right Ventricular Failure","volume":"7","author":"Das","year":"2024","journal-title":"JHLT Open"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Galie","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1801916","DOI":"10.1183\/13993003.01916-2018","article-title":"Paediatric pulmonary arterial hypertension: Updates on definition, classification, diagnostics and management","volume":"53","author":"Rosenzweig","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jacc.2016.05.047","article-title":"Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension: A Pathophysiological Continuum","volume":"68","author":"Opitz","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.jacc.2018.12.076","article-title":"Anatomy, Function, and Dysfunction of the Right Ventricle: JACC State-of-the-Art Review","volume":"73","author":"Sanz","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"016031","DOI":"10.1161\/JAHA.119.016031","article-title":"Multi-beat right ventricular-arterial coupling predicts clinical worsening in pulmonary arterial hypertension","volume":"9","author":"Hsu","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_11","first-page":"R1021","article-title":"Ventricular efficiency predicted by an analytical model","volume":"250","author":"Burkhoff","year":"1986","journal-title":"Am. J. Physiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e006591","DOI":"10.1161\/CIRCHEARTFAILURE.119.006591","article-title":"Effective arterial elastance in the pulmonary artery circulation","volume":"13","author":"Brener","year":"2020","journal-title":"Circ. Heart Fail."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.healun.2023.12.009","article-title":"Advanced hemodynamic and cluster analysis for identifying novel RV function subphenotypes in patients with pulmonary hypertension","volume":"43","author":"Janowski","year":"2024","journal-title":"J. Heart Lung Transplant."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1161\/CIRCRESAHA.121.318241","article-title":"Cardiac Energy Metabolism in Heart Failure","volume":"128","author":"Lopaschuk","year":"2021","journal-title":"Circ. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1161\/01.CIR.94.11.2837","article-title":"Fatty acid oxidation enzyme-encoding gene expression is downregulated in the failing heart","volume":"94","author":"Sack","year":"1996","journal-title":"Circulation"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12265-023-10432-3","article-title":"Cardiac metabolism, rerogramming and diseases","volume":"17","author":"Wang","year":"2023","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Sydykov, A., Mamazhakypov, A., Petrovic, A., Kosanovic, D., Sarybaev, A.S., Weissmann, N., Ghofrani, H.A., and Schermuly, R.T. (2018). Inflammatory mediators drive adverse right ventricular remodeling and dysfunction and serve as potential biomarkers. Front. Physiol., 9.","DOI":"10.3389\/fphys.2018.00609"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.matbio.2018.01.010","article-title":"Right ventricular fibrosis and dysfunction: Actual concepts and common misconceptions","volume":"68","author":"Egemnazarov","year":"2018","journal-title":"Matrix Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2174\/138161282104141204124129","article-title":"Targeting cardiomyocyte Ca2+ homeostasis in heart failure","volume":"21","author":"Roe","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.cardfail.2013.08.004","article-title":"Right Ventricular Afterload and the Role of Nitric Oxide Metabolism in Left-Sided Heart Failure","volume":"19","author":"Dupont","year":"2013","journal-title":"J. Card. Fail."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41569-021-00646-w","article-title":"Transforming growth factor-beta in myocardial disease","volume":"19","author":"Frangogiannis","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3390\/antiox13030312","article-title":"Reactive Oxygen Species Signaling and Oxidative Stress: Transcriptional Regulation and Evolution","volume":"312","author":"Hong","year":"2024","journal-title":"Antioxidants"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Hautbergue, T., Antigny, F., Bo\u00ebt, A., Haddad, F., Masson, B., Lambert, M., Delaporte, A., Menager, J.-B., Savale, L., and Le Pavec, J. (2021). Right Ventricle Remodeling Metabolic Signature in Experimental Pulmonary Hypertension Models of Chronic Hypoxia and Monocrotaline Exposure. Cells, 10.","DOI":"10.3390\/cells10061559"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/hr.2015.153","article-title":"Reversal of right ventricular remodeling by dichloroacetate is related to inhibition of mitochondria-dependent apoptosis","volume":"39","author":"Sun","year":"2016","journal-title":"Hypertens. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00109-011-0804-9","article-title":"Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: Exploiting Randle\u2019s cycle","volume":"90","author":"Fang","year":"2012","journal-title":"J. Mol. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cardfail.2020.10.006","article-title":"Ranolazine improves right ventricular function in patients with precapillary pulmonary hypertension: Results from a double-blind, randomized, placebo-controlled trial","volume":"27","author":"Han","year":"2021","journal-title":"J. Card. Fail."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1165\/rcmb.2019-0226PS","article-title":"Activation of the Metabolic Master Regulator PPARgamma: A Potential PIOneering Therapy for Pulmonary Arterial Hypertension","volume":"62","author":"Hansmann","year":"2020","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Liang, S., Yegambaram, M., Wang, T., Wang, J., Black, S.M., and Tang, H. (2022). Mitochondrial metabolism, redox, and calcium homeostasis in pulmonary arterial hypertension. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020341"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.redox.2014.06.010","article-title":"Coenzyme Q supplementation in pulmonary arterial hypertension","volume":"2","author":"Sharp","year":"2014","journal-title":"Redox Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"018349","DOI":"10.1161\/JAHA.120.018349","article-title":"Mechanistic Phase II Clinical Trial of Metformin in Pulmonary Arterial Hypertension","volume":"9","author":"Brittain","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1177\/15353702231191178","article-title":"Metformin inhibits mitochondrial dysfunction and apoptosis in cardiomyocytes induced by high glucose by upregulating AMPK activity","volume":"248","author":"Wu","year":"2023","journal-title":"Exp. Biol. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1007\/s10238-023-01051-y","article-title":"Molecular mechanisms of action of metformin: Latest advances and therapeutic implications","volume":"23","author":"Zhu","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Mussbacher, M., Derler, M., Bas\u00edlio, J., and Schmid, J.A. (2023). NF-\u03baB in monocytes and macrophages\u2014An inflammatory master regulator in multitalented immune cells. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1134661"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Mamazhakypov, A., Maripov, A., Sarybaev, A.S., Schermuly, R.T., and Sydykov, A. (2024). Mast Cells in Cardiac Remodeling: Focus on the Right Ventricle. J. Cardiovasc. Dev. Dis., 11.","DOI":"10.3390\/jcdd11020054"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imr.12634","article-title":"Mast cells as sources of cytokines, chemokines, and growth factors","volume":"282","author":"Mukai","year":"2018","journal-title":"Immunol. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Mamazhakypov, A., Sommer, N., Assmus, B., Tello, K., Schermuly, R.T., Kosanovic, D., Sarybaev, A.S., Weissmann, N., and Pak, O. (2021). Novel Therapeutic Targets for the Treatment of Right Ventricular Remodeling: Insights from the Pulmonary Artery Banding Model. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18168297"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/cvr\/cvx159","article-title":"Role of cardiac inflammation in right ventricular failure","volume":"113","author":"Sun","year":"2017","journal-title":"Cardiovasc. Res."},{"key":"ref_38","first-page":"235","article-title":"Role of Oxygen Starvation in Right Ventricular Decompensation and Failure in Pulmonary Arterial Hypertension","volume":"12","author":"Zajda","year":"2024","journal-title":"J. Am. Coll. Cardiol. Heart Fail."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.21037\/cdt-20-592","article-title":"Emerging therapies for right ventricular dysfunction and failure","volume":"10","author":"Klinke","year":"2020","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Ramalingam, A., Budin, S.B., Fauzi, N.M., Ritchie, R.H., and Zainalabidin, S. (2021). Targeting mitochondrial reactive oxygen species-mediated oxidative stress attenuates nicotine-induced cardiac remodeling and dysfunction. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-93234-4"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s13287-024-04009-3","article-title":"Cell-based therapies reverse the heart failure-altered right ventricular proteome towards a pre-disease state","volume":"15","author":"Makkaoui","year":"2024","journal-title":"Stem Cell Res. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1038\/s41467-025-56384-x","article-title":"Cardiac repair using regenerating neonatal heart tissue-derived extracellular vesicles","volume":"16","author":"Li","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_43","first-page":"2361012","article-title":"SGLT2 inhibitors as a potential therapeutic option for pulmonary hypertension: Mechanisms and clinical perspectives","volume":"1","author":"Tan","year":"2024","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11897-018-0389-5","article-title":"Novel Insights and Treatment Strategies for Right Heart Failure","volume":"15","author":"Lin","year":"2018","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Das, B.B. (2024). Unlocking the Potential: Angiotensin Receptor Neprilysin and Sodium Glucose Co-Transporter 2 Inhibitors for Right Ventricle Dysfunction in Heart Failure. Medicina, 60.","DOI":"10.3390\/medicina60071112"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"01081","DOI":"10.1186\/s13098-023-01081-2","article-title":"Comparing angiotensin receptor\u2013neprilysin inhibitors with sodium\u2013glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus","volume":"15","author":"Tsai","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors","volume":"75","author":"Zelniker","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling\/Autophagy Hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Giannattasio, S., Citarella, A., Trocchianesi, S., Filardi, T., Morano, S., Lenzi, A., Ferretti, E., and Crescioli, C. (2022). Cell-Target-Specific Anti-Inflammatory Effect of Empagliflozin: In Vitro Evidence in Human Cardiomyocytes. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.879522"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/jdi.13255","article-title":"Sodium\u2013glucose cotransporters: Functional properties and pharmaceutical potential","volume":"11","author":"Sano","year":"2020","journal-title":"J. Diabetes Investig."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Benes, J., Kotrc, M., Wohlfahrt, P., Kroupova, K., Tupy, M., Kautzner, J., and Melenovsky, V. (2023). Right ventricular global dysfunction score: A new concept of right ventricular function assessment in patients with heart failure with reduced ejection fraction (HFrEF). Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1194174"},{"key":"ref_52","first-page":"831","article-title":"Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure with Reduced Ejection Fraction with or Without Diabetes","volume":"4","author":"Yurista","year":"2019","journal-title":"J. Am. Coll. Cardiol. Basic Transl. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/FJC.0000000000001380","article-title":"Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value","volume":"81","author":"Xie","year":"2023","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/ejhf.580","article-title":"Efficacy of sacubitril\/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: The PARADIGM-HF trial","volume":"18","author":"Vardeny","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0002-9149(00)01452-1","article-title":"Angiotensin-converting enzyme inhibitors in adults after the Mustard procedure","volume":"87","author":"Hechter","year":"2001","journal-title":"Am. J. Cardiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijcard.2010.08.068","article-title":"Safety and efficiency of chronic ACE inhibition in symptomatic heart failure patients with a systemic right ventricle","volume":"154","author":"Tutarel","year":"2012","journal-title":"Int. J. Cardiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1001\/jama.2021.18463","article-title":"Effect of Sacubitril\/Valsartan vs. Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients with Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial","volume":"326","author":"Pieske","year":"2021","journal-title":"JAMA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"12821","DOI":"10.1001\/jama.2019.12821","article-title":"Association of Change in N-Terminal Pro\u2013B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment with Cardiac Structure and Function in Patients with Heart Failure with Reduced Ejection Fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Lin, Y., Zhang, H., Zhao, S., Chen, L., Li, J., Wang, X., and Tian, W. (2022). The Efficacy and Safety of the Combined Therapy of Sodium-Glucose Co-Transporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitor in Patients with Heart Failure with Reduced Ejection Fraction: A Meta-Analysis of the EMPEROR-Reduced and DAPA-HF Sub-Analysis. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.882089"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/clc.24085","article-title":"Efficacy of sacubitril-valsartan and SGLT2 inhibitors in heart failure with reduced ejection fraction: A systematic review and meta-analysis","volume":"46","author":"Mo","year":"2023","journal-title":"Clin. Cardiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1111\/cts.13677","article-title":"Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science","volume":"16","author":"Trujillo","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"H8","DOI":"10.1152\/ajpheart.01147.2003","article-title":"Nitric oxide\u2019s role in the heart: Control of beating or breathing?","volume":"287","author":"Paulus","year":"2004","journal-title":"Am. J. Physiol.-Heart Circ. Physiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"220061","DOI":"10.1183\/16000617.0061-2022","article-title":"Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","volume":"31","author":"Benza","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/bcpt.13714","article-title":"Sacubitril\/valsartan, sodium-glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy","volume":"130","author":"Norre","year":"2022","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e662","DOI":"10.1097\/FJC.0000000000001111","article-title":"Safety and Efficacy of the Combination of Sacubitril\/Valsartan and SGLT2i in HFrEF Patients (SECSI Registry)","volume":"78","author":"Valle","year":"2021","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1161\/CIRCULATIONAHA.113.005698","article-title":"STARTS-2: Long-term survival with oral sildenafil monotherapy in treatment-na\u00efve pediatric pulmonary arterial hypertension","volume":"129","author":"Barst","year":"2014","journal-title":"Circulation"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/CIRCULATIONAHA.110.016667","article-title":"A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-na\u00efve children with pulmonary arterial hypertension","volume":"125","author":"Barst","year":"2012","journal-title":"Circulation"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"20458940211024955","DOI":"10.1177\/20458940211024955","article-title":"Efficacy and safety of tadalafil in a pediatric population with pulmonary arterial hypertension: Phase3 randomized, double-blind placebo-controlled study","volume":"11","author":"Ivy","year":"2021","journal-title":"Pulm. Circ."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1111\/bcp.14039","article-title":"Pharmacokinetics and safety of tadalafil in a paediatric population with pulmonary arterial hypertension: A multiple ascending-dose study","volume":"85","author":"Small","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijcard.2015.08.080","article-title":"FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion","volume":"202","author":"Berger","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/bcp.13267","article-title":"A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3","volume":"83","author":"Berger","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_73","first-page":"100055","article-title":"A randomized study of safety and efficacy of two doses of ambrisentan to treat pulmonary arterial hypertension in pediatric patients aged 8years up to 18 years","volume":"5","author":"Ivy","year":"2020","journal-title":"J. Pediatr."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ppul.22555","article-title":"Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension","volume":"48","author":"Takatsuki","year":"2013","journal-title":"Pediatr. Pulmonol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2045894018759247","DOI":"10.1177\/2045894018759247","article-title":"Right ventricular function mirrors clinical improvement with use of prostacyclin analogues in pediatric pulmonary hypertension","volume":"8","author":"Hopper","year":"2018","journal-title":"Pulm. Circ."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1136\/hrt.2006.096412","article-title":"Epoprostenol treatment in children with severe pulmonary hypertension","volume":"93","author":"Lammers","year":"2007","journal-title":"Heart"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2045894020944858","DOI":"10.1177\/2045894020944858","article-title":"Prostanoids in pediatric pulmonary hypertension: Clinical response, time-to-effect, and dose-response","volume":"10","author":"Tella","year":"2020","journal-title":"Pulm. Circ."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/DHPS.S372239","article-title":"Therapeutic Potential of Treprostinil Inhalation Powder for Patients with Pulmonary Arterial Hypertension: Evidence to Date","volume":"16","author":"Cassady","year":"2024","journal-title":"Drug Healthc. Patient Saf."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.amjcard.2010.06.064","article-title":"Long-Term Outcomes in Children with Pulmonary Arterial Hypertension Treated with Bosentan in Real-World Clinical Settings","volume":"106","author":"Ivy","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/ehjqcco\/qcad020","article-title":"Long-term outcome of children with newly diagnosed pulmonary arterial hypertension: Results from the global TOPP registry","volume":"10","author":"Ploegstra","year":"2024","journal-title":"Eur. Heart J.-Qual. Care Clin. Outcomes"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000334431","article-title":"Combination therapy in pulmonary arterial hypertension: A meta-analysis","volume":"120","author":"Bai","year":"2011","journal-title":"Cardiology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.cjca.2016.03.004","article-title":"Combination Therapy for Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis","volume":"32","author":"Fox","year":"2016","journal-title":"Can. J. Cardiol."},{"key":"ref_83","first-page":"249","article-title":"A Network Meta-analysis of the Efficacy and Safety of Targeted Drug Combinations in the Treatment of Pulmonary Arterial Hypertension","volume":"3","author":"Wang","year":"2023","journal-title":"Cardiol. Discov."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"20458940211052823","DOI":"10.1177\/20458940211052823","article-title":"Positioning imatinib for pulmonary arterial hypertension: A phase I\/II design comprising dose finding and single-arm efficacy","volume":"11","author":"Wilkins","year":"2021","journal-title":"Pulm. Circ."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e12352","DOI":"10.1002\/pul2.12352","article-title":"IMPAHCT: A randomized phase 2b\/3 study of inhaled imatinib for pulmonary arterial hypertension","volume":"14","author":"Gillies","year":"2024","journal-title":"Pulm. Circ."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S2213-2600(24)00072-9","article-title":"Seralutinib in adults with pulmonary arterial hypertension (TORREY): A randomized, double-blind, placebo-controlled phase 2 trial","volume":"12","author":"Frantz","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension","volume":"384","author":"Humbert","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1164\/rccm.201906-1141OC","article-title":"Characterization of GDF2 Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension","volume":"201","author":"Hodgson","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1042\/BST20180137","article-title":"Advances in the molecular regulation of endothelial BMP9 signaling complexes and implications for cardiovascular disease","volume":"47","author":"Wood","year":"2019","journal-title":"Biochem. Soc. Trans."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1602337","DOI":"10.1183\/13993003.02337-2016","article-title":"Estrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects","volume":"50","author":"Chen","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"H1708","DOI":"10.1152\/ajpheart.00746.2012","article-title":"Dehydroepiandrosterone restores right ventricular structure and function in rats with severe pulmonary arterial hypertension","volume":"304","author":"Alzoubi","year":"2013","journal-title":"Am. J. Physiol.-Heart Circ. Physiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/01.RES.0000145360.16770.9f","article-title":"Dichloroacetate Prevents and Reverses Pulmonary Hypertension by Inducing Pulmonary Artery Smooth Muscle Cell Apoptosis","volume":"95","author":"McMurtry","year":"2004","journal-title":"Circ. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1136\/thoraxjnl-2020-215266","article-title":"Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19","volume":"76","author":"Khan","year":"2021","journal-title":"Thorax"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Sarapultsev, A., Gusev, E., Komelkova, M., Utepova, I., Luo, S., and Hu, D. (2023). JAK-STAT signaling in inflammation and stress-related diseases: Implications for therapeutic interventions. Mol. Biomed., 4.","DOI":"10.1186\/s43556-023-00151-1"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Feij\u00f3o-Band\u00edn, S., Arag\u00f3n-Herrera, A., Rodr\u00edguez-Penas, D., Portol\u00e9s, M., Rosell\u00f3-Llet\u00ed, E., Rivera, M., Gonz\u00e1lez-Juanatey, J.R., and Lago, F. (2017). Relaxin-2 in Cardiometabolic Diseases: Mechanisms of Action and Future Perspectives. Front. Physiol., 8.","DOI":"10.3389\/fphys.2017.00599"},{"key":"ref_97","first-page":"6942","article-title":"Rho signaling pathway enhances proliferation of PASMCs by suppressing nuclear translocation of Smad1 in PAH","volume":"17","author":"Wei","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1183\/09031936.00130209","article-title":"Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: Comparison with bosentan and sildenafil","volume":"36","author":"Mouchaers","year":"2010","journal-title":"Eur. Respir. J."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jaci.2023.03.030","article-title":"Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease","volume":"152","author":"Laidlaw","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Lou, G., Li, A., Cen, Y., Yang, Q., Zhang, T., Qi, J., Chen, Z., and Liu, Y. (2021). Selonsertib, a potential drug for liver failure therapy by rescuing the mitochondrial dysfunction of macrophage via ASK1\u2013JNK\u2013DRP1 pathway. Cell Biosci., 11.","DOI":"10.1186\/s13578-020-00525-w"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"107576","DOI":"10.1016\/j.pharmthera.2020.107576","article-title":"Pulmonary arterial hypertension specific therapy: The old and the new","volume":"214","author":"Zolty","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Cassady, S.J., Soldin, D., and Ramani, G.V. (2022). Novel and emerging therapies in pulmonary arterial hypertension. Front. Drug Discov., 2.","DOI":"10.3389\/fddsv.2022.1022971"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e12088","DOI":"10.1002\/pul2.12088","article-title":"A trial design to maximize knowledge of the effects of rodatristat ethyl in the treatment of pulmonary arterial hypertension (ELEVATE 2)","volume":"12","author":"Lazarus","year":"2022","journal-title":"Pulm. Circ."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1183\/09031936.00050008","article-title":"Inhalation of vasoactive intestinal peptide in pulmonary hypertension","volume":"32","author":"Leuchte","year":"2008","journal-title":"Eur. Respir."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1161\/ATVBAHA.109.202028","article-title":"Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline","volume":"30","author":"Caruso","year":"2010","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"L521","DOI":"10.1152\/ajplung.00316.2011","article-title":"miR-21 regulates chronic hypoxia-induced pulmonary vascular remodeling","volume":"302","author":"Yang","year":"2012","journal-title":"Am. J. Physiol. Cell. Mol. Physiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/abbs\/gmp049","article-title":"BMPRII is a direct target of miR-21","volume":"41","author":"Qin","year":"2009","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1165\/rcmb.2014-0166TR","article-title":"MicroRNAs in pulmonary arterial hypertension","volume":"52","author":"Zhou","year":"2015","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Pattathu, J., Michel, S., Tengler, A.I., Mandilaras, G., Jakob, A., Pozza, R.D., and Haas, N.A. (2023). Case report: Beneficial longterm effect of the atrial-flow-regulator device in a pediatric patient with idiopathic pulmonary arterial hypertension and recurring syncope. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1197985"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Youssef, D.E., Averin, K., Richards, S., Sheppard, C., Seaman, C., Pietrosanu, M., and Bates, A. (2023). North American, single center experience implanting fenestrated atrial devices and atrial flow regulators into a heterogeneous group of pediatric pulmonary hypertension patients. Front. Pediatr., 11.","DOI":"10.3389\/fped.2023.1073336"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Butera, G., Piccinelli, E., Kolesnik, A., Averin, K., Seaman, C., Castaldi, B., Cuppini, E., Fraisse, A., Bautista-Rodriguez, C., and Hascoet, S. (2024). Implantation of atrial flow regulator devices in patients with congenital heart disease and children with severe pulmonary hypertension or cardiomyopathy\u2014An international multicenter case series. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1332395"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1164\/rccm.202410-1901ST","article-title":"Interventional Strategies for Children with Progressive Pulmonary Hypertension Despite Optimal Therapy. An Official American Thoracic Society Clinical Practice Guideline","volume":"211","author":"Hayes","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jtcvs.2019.10.149","article-title":"A novel unidirectional-valved shunt approach for end-stage pulmonary arterial hypertension: Early experience in adolescents and adults","volume":"161","author":"Rosenzweig","year":"2021","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.healun.2022.07.020","article-title":"The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-fifth pediatric lung transplantation report\u20132022; focus on pulmonary vascular diseases","volume":"41","author":"Hayes","year":"2022","journal-title":"J. Heart Lung Transplant."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.athoracsur.2021.04.032","article-title":"Improved Outcomes of Infant Lung Transplantation Over 3 Decades","volume":"114","author":"Carvajal","year":"2022","journal-title":"Ann. Thorac. Surg."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e14236","DOI":"10.1111\/petr.14236","article-title":"Recovery of right ventricular function after bilateral lung transplantation for pediatric pulmonary hypertension","volume":"26","author":"Critser","year":"2022","journal-title":"Pediatr. Transplant."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41390-020-01113-x","article-title":"Pediatric pulmonary hypertension: Insulin-like growth factor-binding protein 2 is a novel marker associated with disease severity and survival","volume":"88","author":"Griffiths","year":"2020","journal-title":"Pediatr. Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jpeds.2020.04.041","article-title":"Elevated interleukin-6 levels predict clinical worsening in pediatric pulmonary arterial hypertension","volume":"223","author":"Chen","year":"2020","journal-title":"J. Pediatr."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.chest.2021.01.085","article-title":"ST2 is a biomarker of pediatric pulmonary arterial hypertension severity and clinical worsening","volume":"160","author":"Griffiths","year":"2021","journal-title":"Chest"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2045894019859480","DOI":"10.1177\/2045894019859480","article-title":"The expression of survivin in irreversible pulmonary arterial hypertension rats and its value in evaluating the reversibility of pulmonary arterial hypertension secondary to congenital heart disease","volume":"9","author":"Li","year":"2019","journal-title":"Pulm. Circ."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"4957147","DOI":"10.1155\/2017\/4957147","article-title":"Circulating miRNAs in pediatric pulmonary hypertension show promise as biomarkers of vascular function","volume":"2017","author":"Kheyfets","year":"2017","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fped.2014.00007","article-title":"Biomarkers for pediatric pulmonary arterial hypertension\u2014A call to collaborate","volume":"2","author":"Colvin","year":"2014","journal-title":"Front Pediatr."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e12133","DOI":"10.1002\/pul2.12133","article-title":"Riociguat in children with pulmonary arterial hypertension: The PATENT-CHILD study","volume":"12","author":"Gorenflo","year":"2022","journal-title":"Pulm. Circ."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Domingo, L.T., Ivy, D.D., Abman, S.H., Grenolds, A.M., MacLean, J.T., Breaux, J.A., Minford, K.J., and Frank, B.S. (2022). Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide. Front. Pediatr., 10.","DOI":"10.3389\/fped.2022.1014922"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1161\/ATVBAHA.120.315052","article-title":"Stem\/Progenitor Cells and Pulmonary Arterial Hypertension","volume":"41","author":"Pu","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.healun.2022.02.020","article-title":"Stem cell therapy for pulmonary arterial hypertension: An update","volume":"41","author":"Sun","year":"2022","journal-title":"J. Heart Lung Transplant."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jpeds.2020.05.051","article-title":"The genetic epidemiology of pediatric pulmonary arterial hypertension","volume":"225","author":"Haarman","year":"2020","journal-title":"J. Pediatr."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1109\/TBME.2018.2889669","article-title":"A review of low-intensity pulsed ultrasound for therapeutic applications","volume":"66","author":"Jiang","year":"2019","journal-title":"IEEE Trans. Biomed. Eng."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3400\/avd.ra.20-00010","article-title":"Therapeutic angiogenesis with sound waves","volume":"13","author":"Shindo","year":"2020","journal-title":"Ann. Vasc. Dis."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jacbts.2022.08.010","article-title":"Beneficial Effects of Low-Intensity Pulsed Ultrasound Therapy on Right Ventricular Dysfunction in Animal Models","volume":"8","author":"Nakata","year":"2023","journal-title":"JACC Basic Transl. Sci."}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/12\/4\/476\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:11:33Z","timestamp":1760029893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/12\/4\/476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":130,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["children12040476"],"URL":"https:\/\/doi.org\/10.3390\/children12040476","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]}}}